Mumbai-based Truemeds, one of the fastest-growing digital-first healthtech D2C brands India, has raised $20 million (INR 174 Cr) in a fresh infusion from Peak XV Partners as part of its extended Series C funding round. This brings the total funding in its Series C round to $64 million, making Truemeds a strong player in the D2C startup news and Indian D2C updates landscape.
The direct-to-consumer India brand issued 19,737 Series C2 CCPS at a premium of INR 88,231 per share, as per MCA filings accessed by Inc42. With this, the company’s post-money valuation has now crossed $400 million, placing it among the top funded D2C brands in the healthcare category.
Truemeds plans to use the capital to accelerate its D2C expansion plans, scale its tech infrastructure, and enhance consumer experience across its D2C business model India. This fresh funding builds on its earlier $44 million round led by Accel India in March 2025, which also included participation from WestBridge, Konark Trust, MMPL Trust, and IE Venture Fund.
Founded by Akshat Nayyar and Kunal Wani, Truemeds operates a unique D2C healthtech platform where users can upload prescriptions and receive affordable alternatives to expensive branded medicines. The platform provides generic medicine recommendations, along with a curated list of vitamins, supplements, personal care products, and diagnostic tools. This innovation in D2C healthcare is reshaping consumer habits in tier 1 to tier 3 cities — a key theme in current D2C consumer behavior India.
The startup’s D2C revenue growth has attracted top-tier investors like WestBridge and 3one4 Capital in prior rounds, reflecting strong VC-backed D2C brand interest. In total, Truemeds has raised over $90 million across all its funding rounds. Prior to the Series C round, the company secured $22 million in Series B (2022) and $5 million in Series A (2021).
The latest investment also comes at a crucial time for Peak XV, which is reportedly raising its first independent fund post-Sequoia split, targeting $1.2–1.4 billion to back high-growth startups across India and Southeast Asia. Truemeds’ inclusion in this strategy reinforces its prominence in the D2C ecosystem India.
On a macro level, D2C industry news and healthtech funding trends in H1 2025 indicate renewed momentum. According to Inc42, the healthtech sector secured $377 million across 29 deals, ranking fourth among India’s most funded sectors after fintech, ecommerce, and enterprise tech. Truemeds and unicorn Innovaccer led the surge, with Innovaccer bagging $275 million in Series F from B Capital and others.
With its clear focus on affordability, accessibility, and digital convenience, Truemeds is setting new benchmarks in the D2C healthtech segment. Its Series C success story underscores growing investor confidence in D2C brands scaling in 2025, especially those with a strong mission-driven model and omnichannel D2C strategy.